Loading...

ANNX ANNEXON INC Investments/Divestments 8-K Filing

NNXN

NNX

ANNEXON INC

(ANNX)

2023 8-K

Show Summary

Summary

Financial Results

Common Warrant Amendments

Financial Statements

Financial Results

2025 Outlook Announcement

Director Appointment

Positive Study Results

Q3 2024 Results

Q2 2024 Results

Update on ARCHER II Global ...

Positive Phase 3 Results fo...

Annual Meeting Voting Results

Underwriting Agreement

Phase 3 Trial Results

Financial Results Announcement

Financial Results

R&D Day Presentation

Filing Correction and Under...

Entry into a Material Defin...

Global Registrational Progr...

Financial Results

Financial Results

Appointment, Trial Results

Annual Meeting Voting Results

Results Announcement

Financial Results

Financial Results Announcement

Investor Conferences

Appointment of Chief Scient...

External Links:

Annexon, Inc. announced topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA), demonstrating statistically significant preservation of visual function.

AI Assistant

ANNEXON INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.